中华医学会近期发布的慢性乙型肝炎防治指南(2022年版)重点强调了对于乙型肝炎病毒(hepatitis B virus,HBV)慢性感染者需要逐渐扩大抗病毒治疗适应证。只要符合标准,应尽早启动抗病毒治疗,以阻止疾病进展。在抗病毒治疗人群选择上,指南...中华医学会近期发布的慢性乙型肝炎防治指南(2022年版)重点强调了对于乙型肝炎病毒(hepatitis B virus,HBV)慢性感染者需要逐渐扩大抗病毒治疗适应证。只要符合标准,应尽早启动抗病毒治疗,以阻止疾病进展。在抗病毒治疗人群选择上,指南更强调除了关注病毒学、血清学和肝脏生化学指标外,疾病的严重程度是启动抗病毒治疗的重要指标,疾病越重,抗病毒治疗需越积极。此外,还强调对于不同的疾病状态,可采用不同的治疗策略。展开更多
Liver fibrosis is a pathological condition characterized by replacement of normal liver tissue with scar tissue,and also the leading cause of liver-related death worldwide.During the treatment of liver fibrosis,in add...Liver fibrosis is a pathological condition characterized by replacement of normal liver tissue with scar tissue,and also the leading cause of liver-related death worldwide.During the treatment of liver fibrosis,in addition to antiviral therapy or removal of inducers,there remains a lack of specific and effective treatment strategies.For thousands of years,Chinese herbal medicines(CHMs)have been widely used to treat liver fibrosis in clinical setting.CHMs are effective for liver fibrosis,though its mechanisms of action are unclear.In recent years,many studies have attempted to determine the possible mechanisms of action of CHMs in treating liver fibrosis.There have been substantial improvements in the experimental investigation of CHMs which have greatly promoted the understanding of anti-liver fibrosis mechanisms.In this review,the role of CHMs in the treatment of liver fibrosis is described,based on studies over the past decade,which has addressed the various mechanisms and signaling pathways that mediate therapeutic efficacy.Among them,inhibition of stellate cell activation is identified as the most common mechanism.This article provides insights into the research direction of CHMs,in order to expand its clinical application range and improve its effectiveness.展开更多
文摘中华医学会近期发布的慢性乙型肝炎防治指南(2022年版)重点强调了对于乙型肝炎病毒(hepatitis B virus,HBV)慢性感染者需要逐渐扩大抗病毒治疗适应证。只要符合标准,应尽早启动抗病毒治疗,以阻止疾病进展。在抗病毒治疗人群选择上,指南更强调除了关注病毒学、血清学和肝脏生化学指标外,疾病的严重程度是启动抗病毒治疗的重要指标,疾病越重,抗病毒治疗需越积极。此外,还强调对于不同的疾病状态,可采用不同的治疗策略。
基金Liaoning Provincial Local Professional Technology Innovation Platform Construction Project(2016007013)Liaoning Provincial Natural Science Foundation(2014021007)+2 种基金Outstanding Scientiffc Fund of Shengjing Hospital(2011-02)345 Talent Project of Shengjing Hospital(2020-01)The Mechanism of Immune Tolerance Mediated by Myeloid-Derived Suppressor Cells inhibiting T Cell Immune Responses via PD-L1 in Chronic Hepatits B(2022-12).
文摘Liver fibrosis is a pathological condition characterized by replacement of normal liver tissue with scar tissue,and also the leading cause of liver-related death worldwide.During the treatment of liver fibrosis,in addition to antiviral therapy or removal of inducers,there remains a lack of specific and effective treatment strategies.For thousands of years,Chinese herbal medicines(CHMs)have been widely used to treat liver fibrosis in clinical setting.CHMs are effective for liver fibrosis,though its mechanisms of action are unclear.In recent years,many studies have attempted to determine the possible mechanisms of action of CHMs in treating liver fibrosis.There have been substantial improvements in the experimental investigation of CHMs which have greatly promoted the understanding of anti-liver fibrosis mechanisms.In this review,the role of CHMs in the treatment of liver fibrosis is described,based on studies over the past decade,which has addressed the various mechanisms and signaling pathways that mediate therapeutic efficacy.Among them,inhibition of stellate cell activation is identified as the most common mechanism.This article provides insights into the research direction of CHMs,in order to expand its clinical application range and improve its effectiveness.
